Selpercatinib

證據等級: L5

預測適應症: 3 個

Selpercatinib: From RET-Altered Cancer to Pulmonary Hypertension

One-Sentence Summary

Selpercatinib is a selective RET kinase inhibitor used in RET fusion/mutation-positive cancers (based on literature context; formal original-indication data is not yet populated). The TxGNN model predicts a possible effect in pulmonary hypertension, but a review of the 3 supporting publications found none actually address pulmonary vascular disease — the top prediction currently has no real mechanistic or clinical support.

Quick Overview

Item	Content
Original Indication	Not available in structured data (data gap); literature context suggests RET fusion/mutation-positive cancers (e.g., NSCLC, medullary thyroid carcinoma)
Predicted New Indication	Pulmonary Hypertension
TxGNN Prediction Score	99.18% (rank 8099)
Evidence Level	L5 (model prediction only)
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not currently available for selpercatinib (data gap). Based on the literature retrieved for this candidate, selpercatinib is a selective RET tyrosine kinase inhibitor developed for RET fusion-positive NSCLC and RET-mutant medullary thyroid carcinoma — it blocks, rather than activates, RET/GDNF signaling.

There is no established biological rationale linking RET inhibition to pulmonary hypertension. A check of the three cited publications shows none support this connection: the FAERS real-world study (PMID 39372206) reports selpercatinib-associated cardiopulmonary adverse events as pulmonary embolism, deep vein thrombosis, pericardial effusion, and systemic hypertension — not pulmonary hypertension. The other two papers (a retrospective NSCLC analysis and a medullary thyroid carcinoma case report) are unrelated to pulmonary vascular disease and appear to have matched on keyword overlap (RET / hypertension) rather than clinical relevance.

No clinical trials, preclinical studies, or mechanistic literature currently link the GDNF-RET axis to pulmonary vascular remodeling in a therapeutically actionable way. The high TxGNN score therefore reflects a purely data-driven association without corroborating biological or clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39372206	2024	Cohort (FAERS real-world AE analysis)	Frontiers in Pharmacology	Compares adverse-event profiles of pralsetinib vs. selpercatinib; reported cardiopulmonary AEs are pulmonary embolism, DVT, pericardial effusion, and systemic hypertension — not pulmonary hypertension
34178121	2021	Retrospective (SIREN)	Therapeutic Advances in Medical Oncology	Real-world efficacy of selpercatinib in RET fusion-positive NSCLC through an access program; no relevance to pulmonary vascular disease
41918669	2026	Case report	Cureus	Case of MEN2B-associated medullary thyroid carcinoma with RET M918T mutation on targeted therapy; unrelated to pulmonary hypertension

Finland Market Information

Selpercatinib currently holds no marketing authorization in Finland (0 licenses on record).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (selective RET kinase inhibitor) — inferred from literature context; formal DrugBank/MOA classification is a data gap
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. TFDA labeling data (warnings/contraindications) could not be retrieved, which blocks formal safety pre-screening (S1) for this candidate.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but verification of the cited literature shows no actual mechanistic or clinical evidence connecting RET inhibition to pulmonary hypertension, and no clinical trials exist for this indication. Combined with the missing TFDA safety data, this candidate cannot advance past initial screening.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) to unblock safety pre-screening
Confirmed original indication and mechanism-of-action data from DrugBank
Preclinical or mechanistic evidence specifically linking RET/GDNF signaling to pulmonary vascular remodeling before further pursuing this indication
If migraine-related predictions (rank 2/3) are of interest, dedicated literature and trial searches, as none currently exist
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.